Body composition, pre-diabetes and cardiovascular disease risk in early schizophrenia

Early Intervention in Psychiatry
Martin StrassnigRohan Ganguli

Abstract

This preliminary study examines the relationship between body composition, insulin resistance and NCEP-III-defined cardiovascular disease risk factors in persons early in the course of schizophrenia exposed to commonly prescribed atypical antipsychotic medications. Subjects underwent modified oral glucose tolerance tests (OGTTs) and DEXA (dual X-ray absorptiometry) scans corrected for relevant sociodemographic data, including activity levels. We used linear multiple regression models to evaluate relationships between body composition and metabolic variables. Thirty-six individuals diagnosed with schizophrenia, receiving atypical antipsychotic monotherapy, and within 5 years of illness onset, participated. Average age was 25.1 ± 3.6 years (range, 19-34) and duration of illness was 2.5 years (30 ± 18 months). Mean body mass index (BMI) was 28.3 ± 4.9, with a mean total body fat mass of 28.6 ± 8.4%, suggesting an increase in fat relative to BMI. Ten participants (28%) had pre-diabetes (fasting glucose 100-126 mg dL-1 or 2-h OGTT 140-200 mg dL-1 ), but no participant had diabetes. Insulin resistance (HOMA-IR) was predicted by total body mass (BMI) more so than by body fat mass, with an incremental contribution derived from antipsyc...Continue Reading

References

Sep 1, 2000·The American Journal of Clinical Nutrition·D GallagherY Sakamoto
Jul 20, 2001·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·H E Lebovitz
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
May 27, 2003·Schizophrenia Research·Martin StrassnigRohan Ganguli
Oct 14, 2003·Schizophrenia Bulletin·Martin StrassnigRohan Ganguli
Jan 30, 2004·Diabetes Care·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Feb 26, 2004·Obesity Research·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Dec 31, 2004·The American Journal of Psychiatry·Karen A GrahamJoyce B Harp
Dec 20, 2005·Schizophrenia Research·Guy FaulknerGary Remington
Oct 13, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Karen L HouseknechtHans Rollema
Dec 15, 2006·Nature·Jean-Pierre Després, Isabelle Lemieux
Mar 22, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Dan W HauptJohn W Newcomer
Oct 18, 2007·JAMA : the Journal of the American Medical Association·John W Newcomer, Charles H Hennekens
Jan 1, 2009·The American Journal of Clinical Nutrition·Katherine M FlegalNathaniel Schenker
Sep 16, 2009·PloS One·Thomas L KellySteven B Heymsfield
Oct 29, 2009·JAMA : the Journal of the American Medical Association·Christoph U CorrellAnil K Malhotra
Feb 9, 2011·Archives of General Psychiatry·Debra L Foley, Katherine I Morley
Feb 22, 2011·The Psychiatric Clinics of North America·Rohan Ganguli, Martin Strassnig
Mar 8, 2011·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Marc DE HertStefan Leucht
May 28, 2011·Journal of Cellular Physiology·Fabio PanarielloAndrea de Bartolomeis
Jun 3, 2011·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Marc De HertChristoph U Correll
Nov 24, 2011·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·M AshwellS Gibson
Jan 10, 2012·The Journal of Clinical Psychiatry·Peter ManuMarc De Hert
Mar 1, 2012·Journal of Pediatric Health Care : Official Publication of National Association of Pediatric Nurse Associates & Practitioners·Joyce Nolan HarrisonDeborah Gross
May 5, 2012·Annals of General Psychiatry·Norio SugawaraSunao Kaneko
May 26, 2012·Nutrition Research Reviews·E Louise ThomasJimmy D Bell
Dec 21, 2012·The International Journal of Neuropsychopharmacology·W Wolfgang FleischhackerUNKNOWN EUFEST study group
Jan 11, 2013·Clinical Schizophrenia & Related Psychoses·Martin StrassnigRohan Ganguli
Dec 18, 2013·The Journal of Clinical Psychiatry·John W NewcomerRobert W Buchanan

❮ Previous
Next ❯

Citations

Oct 17, 2018·NPJ Schizophrenia·Richard NewtonBenedicto Crespo-Facorro
Dec 21, 2018·Frontiers in Psychiatry·Nicole E MacKenzieMargaret K Hahn
Jan 20, 2021·PloS One·Valentina PrestaGiuliana Gobbi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.